US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US6906093B2
(en)
*
|
1995-06-07 |
2005-06-14 |
Sugen, Inc. |
Indolinone combinatorial libraries and related products and methods for the treatment of disease
|
US6316429B1
(en)
*
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
US6051593A
(en)
*
|
1997-06-20 |
2000-04-18 |
Sugen, Inc. |
3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase inhibitors
|
US6569868B2
(en)
|
1998-04-16 |
2003-05-27 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
NZ508815A
(en)
*
|
1998-05-29 |
2005-02-25 |
Sugen Inc |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
EP1157019B1
(de)
|
1998-12-17 |
2003-03-19 |
F. Hoffmann-La Roche Ag |
4-alkenyl (und alkinyl)oxoindole als inhibitoren cyclinabhängiger kinasen, insbesondere cdk2
|
US6153634A
(en)
*
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
BR9916223A
(pt)
|
1998-12-17 |
2001-09-04 |
Hoffmann La Roche |
4-ariloxindóis como inibidores de cinases de proteìna jnk
|
US20030119895A1
(en)
*
|
1998-12-23 |
2003-06-26 |
Pharmacia Corporation |
Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
|
US6689806B1
(en)
*
|
1999-03-24 |
2004-02-10 |
Sugen, Inc. |
Indolinone compounds as kinase inhibitors
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
US6878733B1
(en)
|
1999-11-24 |
2005-04-12 |
Sugen, Inc. |
Formulations for pharmaceutical agents ionizable as free acids or free bases
|
JP5336686B2
(ja)
*
|
1999-11-24 |
2013-11-06 |
スージェン, インク. |
遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
DE60029138T2
(de)
*
|
1999-12-22 |
2007-06-06 |
Sugen, Inc., San Francisco |
Verwendung von Indolinonverbindungen zur Herstellung von Pharmazeutika für die Modulation der Funktion c-kit Proteintyrosinkinase
|
US6339100B1
(en)
*
|
1999-12-29 |
2002-01-15 |
The Trustees Of Columbia University In The City Of New York |
Methods for inhibiting mastocytosis
|
JP2003535038A
(ja)
*
|
1999-12-30 |
2003-11-25 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節および癌化学療法において用いるための3−ヘテロアリーリデニル−2−インドリノン化合物
|
DE122010000004I1
(de)
*
|
2000-02-15 |
2010-04-15 |
Sugen Inc |
Pyrrol substituierte indolin-2-on protein kinase inhibitoren
|
AU2001255796A1
(en)
|
2000-05-02 |
2001-11-12 |
Sugen, Inc. |
(2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors
|
MY128449A
(en)
*
|
2000-05-24 |
2007-02-28 |
Sugen Inc |
Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
WO2001094312A2
(en)
|
2000-06-02 |
2001-12-13 |
Sugen, Inc. |
Indolinone derivatives as protein kinase/phosphatase inhibitors
|
JP2004502686A
(ja)
|
2000-06-30 |
2004-01-29 |
スージェン・インコーポレーテッド |
4−ヘテロアリール−3−ヘテロアリーリデニル−2−インドリノンおよび蛋白質キナーゼ阻害剤としてのその使用
|
JP2004518669A
(ja)
*
|
2000-12-20 |
2004-06-24 |
スージェン・インコーポレーテッド |
4−アリール置換インドリノン
|
WO2002053596A2
(en)
|
2001-01-05 |
2002-07-11 |
Pfizer Inc. |
Antibodies to insulin-like growth factor i receptor
|
AR042586A1
(es)
|
2001-02-15 |
2005-06-29 |
Sugen Inc |
3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
|
WO2002070478A1
(en)
|
2001-03-06 |
2002-09-12 |
Astrazeneca Ab |
Indolone derivatives having vascular-damaging activity
|
US6797725B2
(en)
|
2001-04-09 |
2004-09-28 |
Sugen, Inc. |
Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
|
JPWO2002094809A1
(ja)
*
|
2001-05-24 |
2004-09-09 |
山之内製薬株式会社 |
3−キノリン−2(1h)−イリデンインドリン−2−オン誘導体
|
PE20030062A1
(es)
*
|
2001-05-30 |
2003-02-08 |
Sugen Inc |
Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
|
AU2002345792A1
(en)
|
2001-06-21 |
2003-01-08 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
DE60223063T2
(de)
|
2001-06-29 |
2008-07-17 |
Ab Science |
C-kit inhibitoren
|
JP2004537542A
(ja)
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
炎症性腸疾患(ibd)を治療するための、チロシンキナーゼ阻害剤の使用
|
JP2004530722A
(ja)
*
|
2001-06-29 |
2004-10-07 |
アブ サイエンス |
骨喪失を治療するためのチロシンキナーゼ阻害剤の使用法
|
JP2004537537A
(ja)
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
|
JP2004537536A
(ja)
|
2001-06-29 |
2004-12-16 |
アブ サイエンス |
アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
EP1434774A1
(de)
|
2001-10-10 |
2004-07-07 |
Sugen, Inc. |
3-(4-substituierte heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivate als protein-kinase-inhibitoren
|
TWI259081B
(en)
*
|
2001-10-26 |
2006-08-01 |
Sugen Inc |
Treatment of acute myeloid leukemia with indolinone compounds
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
BR0215360A
(pt)
|
2001-12-27 |
2004-12-14 |
Theravance Inc |
Derivados de indolina úteis como inibidores de proteìna quinase
|
AU2003206068A1
(en)
|
2002-03-01 |
2003-09-16 |
Pfizer Inc. |
Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
|
JP2005524710A
(ja)
*
|
2002-05-06 |
2005-08-18 |
ジェネンテック・インコーポレーテッド |
骨欠陥の治療へのvegfの用途
|
UA77303C2
(en)
|
2002-06-14 |
2006-11-15 |
Pfizer |
Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
|
EP2447055B1
(de)
|
2002-06-24 |
2017-12-06 |
Tufts University |
Seidenbiomaterialien und Verfahren zu ihrer Verwendung
|
US20050032871A1
(en)
*
|
2002-09-03 |
2005-02-10 |
Sugen, Inc. |
Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors
|
WO2004050681A2
(en)
|
2002-11-15 |
2004-06-17 |
Exelixis, Inc. |
Kinase modulators
|
AR042042A1
(es)
*
|
2002-11-15 |
2005-06-08 |
Sugen Inc |
Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
|
AU2003284572A1
(en)
*
|
2002-11-22 |
2004-06-18 |
Yamanouchi Pharmaceutical Co., Ltd. |
2-oxoindoline derivatives
|
JP4879492B2
(ja)
*
|
2002-11-27 |
2012-02-22 |
アラーガン、インコーポレイテッド |
疾患の治療のためのキナーゼ阻害剤
|
EA008501B1
(ru)
|
2002-12-19 |
2007-06-29 |
Пфайзер Инк. |
2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
|
AP2114A
(en)
|
2003-02-26 |
2010-03-04 |
Sugen Inc |
Aminoheteroaryl compounds as protein kinase inhibitors
|
US7157577B2
(en)
*
|
2003-03-07 |
2007-01-02 |
Sugen Inc. |
5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
|
US20040266843A1
(en)
*
|
2003-03-07 |
2004-12-30 |
Sugen, Inc. |
Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
|
EP1613796B1
(de)
|
2003-04-10 |
2017-03-22 |
Tufts University |
Konzentrierte wässrige seidenfibroinlösung und deren verwendung
|
KR101254371B1
(ko)
|
2003-07-18 |
2013-05-02 |
암젠 프레몬트 인코포레이티드 |
간세포 성장인자에 결합하는 분리된 항체
|
WO2005016875A2
(en)
*
|
2003-08-06 |
2005-02-24 |
Sugen, Inc. |
Geometrically restricted 3-cyclopentylidene-1,3-dihydroindol-2-ones as potent protein kinase inhibitors
|
BRPI0413876A
(pt)
|
2003-08-29 |
2006-10-24 |
Pfizer |
tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
MXPA06004438A
(es)
|
2003-10-24 |
2006-06-20 |
Schering Ag |
Derivados de indolinona y su uso en el tratamiento de enfermedades como el cancer.
|
CA2547283C
(en)
*
|
2003-11-26 |
2010-11-09 |
Pfizer Products Inc. |
Aminopyrazole derivatives as gsk-3 inhibitors
|
MXPA06007242A
(es)
|
2003-12-23 |
2006-08-18 |
Pfizer |
Nuevos derivados de quinolina.
|
EP2277595A3
(de)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Verbindungen zur Immunopotenzierung
|
AU2005276135B2
(en)
|
2004-08-26 |
2011-04-28 |
Pfizer Inc. |
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
|
GT200500321A
(es)
*
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
US7652009B2
(en)
|
2004-11-30 |
2010-01-26 |
Amgem Inc. |
Substituted heterocycles and methods of use
|
WO2006101925A2
(en)
|
2005-03-16 |
2006-09-28 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
|
KR20080003390A
(ko)
|
2005-03-31 |
2008-01-07 |
어젠시스 인코포레이티드 |
161p2f10b 단백질과 결합하는 항체 및 관련 분자
|
MX2007013304A
(es)
|
2005-04-26 |
2007-12-13 |
Pfizer |
Anticuerpos de p-caderina.
|
EP1883403A4
(de)
*
|
2005-04-29 |
2011-02-16 |
Univ Ohio State Res Found |
Keratinocytenwachstumsfaktorrezeptor tyrosinspezifische inhibitoren für die prävention der krebsmetastase
|
TWI453218B
(zh)
|
2005-09-07 |
2014-09-21 |
Amgen Fremont Inc |
針對類活化素受體激酶-1之人類單株抗體
|
EP1926996B1
(de)
|
2005-09-20 |
2011-11-09 |
OSI Pharmaceuticals, Inc. |
Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren
|
US20080108664A1
(en)
|
2005-12-23 |
2008-05-08 |
Liu Belle B |
Solid-state form of AMG 706 and pharmaceutical compositions thereof
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
BRPI0707312B1
(pt)
*
|
2006-01-27 |
2022-06-07 |
Shanghai Hengrui Pharmacetical Co., Ltd |
Inibidores de pirrolo [3,2-c] piridina-4-ona 2-indolinona proteína cinase, seu uso e seu processo de fabricação, intermediário e seus processos de fabricação, composição farmacêutica e seu uso
|
WO2007092178A1
(en)
|
2006-02-10 |
2007-08-16 |
Amgen Inc. |
Hydrate forms of amg706
|
KR100647350B1
(ko)
*
|
2006-04-03 |
2006-11-23 |
김상민 |
시밍장치
|
AR060358A1
(es)
|
2006-04-06 |
2008-06-11 |
Novartis Vaccines & Diagnostic |
Quinazolinas para la inhibicion de pdk 1
|
AU2007240496A1
(en)
|
2006-04-19 |
2007-11-01 |
Novartis Ag |
Indazole compounds and methods for inhibition of CDC7
|
MX2008013990A
(es)
|
2006-05-09 |
2009-01-29 |
Pfizer Prod Inc |
Derivados de cicloalquilamino acidos.
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
WO2008118133A2
(en)
|
2006-09-26 |
2008-10-02 |
Trustees Of Tufts College |
Silk microspheres for encapsulation and controlled release
|
AU2007314521A1
(en)
*
|
2006-10-06 |
2008-05-08 |
Merck Sharp & Dohme Corp. |
Non-nucleoside reverse transcriptase inhibitors
|
CA2672438A1
(en)
|
2006-12-20 |
2008-07-03 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
WO2008086014A2
(en)
|
2007-01-09 |
2008-07-17 |
Amgen Inc. |
Bis-aryl amide derivatives useful for the treatment of cancer
|
AU2008219166B2
(en)
|
2007-02-16 |
2013-05-16 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
|
WO2008106485A2
(en)
|
2007-02-27 |
2008-09-04 |
Trustees Of Tufts College |
Tissue-engineered silk organs
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
ES2529790T3
(es)
|
2007-04-13 |
2015-02-25 |
Dana-Farber Cancer Institute, Inc. |
Métodos de tratamiento de cáncer resistente a agentes terapéuticos de ERBB
|
US9808557B2
(en)
|
2007-08-10 |
2017-11-07 |
Trustees Of Tufts College |
Tubular silk compositions and methods of use thereof
|
PT2188313T
(pt)
|
2007-08-21 |
2017-12-12 |
Amgen Inc |
Proteínas de ligação ao antigénio c-fms humano
|
WO2009030270A1
(en)
*
|
2007-09-03 |
2009-03-12 |
Novartis Ag |
Dihydroindole derivatives useful in parkinson's disease
|
AR069798A1
(es)
|
2007-12-20 |
2010-02-17 |
Novartis Ag |
Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa.
|
US8993615B2
(en)
*
|
2008-08-08 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for treatment of neurodegenerative disease
|
CA2737597C
(en)
|
2008-10-16 |
2017-03-14 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
CN101397295B
(zh)
*
|
2008-11-12 |
2012-04-25 |
深圳微芯生物科技有限责任公司 |
作为组蛋白去乙酰化酶抑制剂的2-吲哚满酮衍生物、其制法和用途
|
SG172857A1
(en)
|
2009-02-09 |
2011-08-29 |
Supergen Inc |
Pyrrolopyrimidinyl axl kinase inhibitors
|
JP2012518657A
(ja)
|
2009-02-25 |
2012-08-16 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
併用抗癌治療
|
JP2012519170A
(ja)
|
2009-02-26 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010098866A1
(en)
|
2009-02-27 |
2010-09-02 |
Supergen, Inc. |
Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8465912B2
(en)
|
2009-02-27 |
2013-06-18 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
EP2454380A2
(de)
|
2009-07-13 |
2012-05-23 |
F. Hoffmann-La Roche AG |
Diagnostische verfahren und zusammensetzungen zur krebsbehandlung
|
US20120128670A1
(en)
|
2009-07-31 |
2012-05-24 |
OSI Pharmaceuticals, LLC |
mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
|
EP2473500A2
(de)
|
2009-09-01 |
2012-07-11 |
Pfizer Inc. |
Benzimidazolderivate
|
JP2013504595A
(ja)
|
2009-09-11 |
2013-02-07 |
ジェネンテック, インコーポレイテッド |
抗癌剤に対する応答の可能性が増加した患者を同定するための方法
|
WO2011033006A1
(en)
|
2009-09-17 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
KR20120116445A
(ko)
|
2009-12-25 |
2012-10-22 |
다이호야쿠힌고교 가부시키가이샤 |
간 세포암 환자에 대한 화학 요법의 치료 효과 예측 방법
|
CA2785389A1
(en)
|
2009-12-25 |
2011-06-30 |
Taiho Pharmaceutical Co., Ltd. |
Antitumor agent or postoperative adjuvant chemotherapeutic agent for hepatocellular carcinoma treatment
|
KR20120127495A
(ko)
|
2010-02-12 |
2012-11-21 |
화이자 인코포레이티드 |
8-플루오로-2-{4-[(메틸아미노)메틸]페닐}-1,3,4,5-테트라하이드로-6h-아제피노[5,4,3-cd]인돌-6-온의 염 및 다형체
|
WO2011109572A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011109584A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
ES2611479T3
(es)
|
2010-06-16 |
2017-05-09 |
University Of Pittsburgh- Of The Commonwealth System Of Higher Education |
Anticuerpos contra endoplasmina y su uso
|
WO2011161217A2
(en)
|
2010-06-23 |
2011-12-29 |
Palacký University in Olomouc |
Targeting of vegfr2
|
BR112013001429A2
(pt)
|
2010-07-19 |
2016-05-31 |
Hoffmann La Roche |
método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer
|
MX2013000667A
(es)
|
2010-07-19 |
2013-02-27 |
Hoffmann La Roche |
Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
|
EP2596026B1
(de)
|
2010-07-23 |
2020-04-08 |
Trustees of Boston University |
Anti-desupr-hemmer als therapeutika zur hemmung der pathologischen angiogenese und invasivität von tumorzellen sowie für molekulare bildgebung und gezielte freisetzung
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
JP5802756B2
(ja)
|
2010-10-20 |
2015-11-04 |
ファイザー・インク |
スムーズンド受容体モジュレーターとしてのピリジン−2−誘導体
|
WO2012104776A1
(en)
|
2011-01-31 |
2012-08-09 |
Novartis Ag |
Novel heterocyclic derivatives
|
WO2012116040A1
(en)
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
EP2937349B1
(de)
|
2011-03-23 |
2016-12-28 |
Amgen Inc. |
Fusionierte tricyclische duale inhibitoren von cdk 4/6 und flt3
|
US9150644B2
(en)
|
2011-04-12 |
2015-10-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
|
CA2830972C
(en)
|
2011-04-19 |
2018-11-20 |
Pfizer Inc. |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
WO2012145652A1
(en)
|
2011-04-20 |
2012-10-26 |
Trustees Of Tufts College |
Dynamic silk coatings for implantable devices
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
PL3409278T3
(pl)
|
2011-07-21 |
2021-02-22 |
Sumitomo Pharma Oncology, Inc. |
Heterocykliczne inhibitory kinazy białkowej
|
WO2013025939A2
(en)
|
2011-08-16 |
2013-02-21 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
JP5914667B2
(ja)
|
2011-09-22 |
2016-05-11 |
ファイザー・インク |
ピロロピリミジンおよびプリン誘導体
|
CA2848842C
(en)
|
2011-10-04 |
2020-09-29 |
King's College London |
Ige anti -hmw-maa antibody
|
EA023935B1
(ru)
|
2011-10-28 |
2016-07-29 |
Новартис Аг |
Производные пурина и их применение для лечения заболевания
|
MX2014005570A
(es)
|
2011-11-08 |
2014-05-30 |
Pfizer |
El uso de anticuerpos anti factor estimulante de la colonia de macrofagos para tratar trastornos inflamatorios.
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
CA2867464A1
(en)
|
2012-03-20 |
2013-09-26 |
Trustees Of Tufts College |
Silk reservoirs for drug delivery
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
AU2013245785A1
(en)
|
2012-04-13 |
2014-10-23 |
Trustees Of Tufts College |
Methods and compositions for preparing a silk microsphere
|
KR101774861B1
(ko)
*
|
2012-04-20 |
2017-09-05 |
안지 파마슈티컬 코퍼레이션 리미티드 |
퓨린 유도체의 사이클로프로판카르복실레이트 에스터
|
SG11201406550QA
(en)
|
2012-05-16 |
2014-11-27 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
US10034945B2
(en)
|
2012-07-13 |
2018-07-31 |
Trustees Of Tufts College |
Silk powder compaction for production of constructs with high mechanical strength and stiffness
|
US9505749B2
(en)
|
2012-08-29 |
2016-11-29 |
Amgen Inc. |
Quinazolinone compounds and derivatives thereof
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
CN102887851B
(zh)
*
|
2012-11-02 |
2014-03-19 |
天津希恩思生化科技有限公司 |
化合物3,5-二甲基-1h-吡咯-2,4-二甲醛及其制备方法
|
US9260426B2
(en)
|
2012-12-14 |
2016-02-16 |
Arrien Pharmaceuticals Llc |
Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
|
MX2015012062A
(es)
|
2013-03-14 |
2016-05-05 |
Tolero Pharmaceuticals Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
US11376329B2
(en)
|
2013-03-15 |
2022-07-05 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
AU2014233480B2
(en)
|
2013-03-15 |
2018-08-09 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
US9206188B2
(en)
|
2013-04-18 |
2015-12-08 |
Arrien Pharmaceuticals Llc |
Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
|
US10285702B2
(en)
|
2013-04-24 |
2019-05-14 |
Trustees Of Tufts College |
Bioresorbable biopolymer anastomosis devices
|
CN105764511B
(zh)
|
2013-10-04 |
2019-01-11 |
艾普托斯生物科学公司 |
用于治疗癌症的组合物和方法
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
ES2899167T3
(es)
|
2013-12-06 |
2022-03-10 |
Novartis Ag |
Régimen posológico para un inhibidor de fosfatidilinositol 3-cinasas selectivo para la isoforma alfa
|
ES2727374T3
(es)
|
2014-04-04 |
2019-10-15 |
Crown Bioscience Inc Taicang |
Gen de fusión HNF4G-RSPO2
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
HUE046518T2
(hu)
|
2014-04-30 |
2020-03-30 |
Pfizer |
Cikloalkilcsoporthoz kapcsolt diheterociklusos származékok
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
JP6811706B2
(ja)
|
2014-07-31 |
2021-01-13 |
ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー |
Epha4に対するヒトモノクローナル抗体及びそれらの使用
|
WO2016100721A1
(en)
|
2014-12-17 |
2016-06-23 |
Tufts University |
Injectable, flexible hydroxyapatite-silk foams for osteochondral and dental repair
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
JP7041515B2
(ja)
|
2015-01-08 |
2022-03-24 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
骨、骨髄、及び軟骨の誘導を提供する因子及び細胞
|
WO2016172214A1
(en)
|
2015-04-20 |
2016-10-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
MX2017013956A
(es)
|
2015-05-01 |
2018-09-05 |
Cocrystal Pharma Inc |
Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer.
|
EP4086264B1
(de)
|
2015-05-18 |
2023-10-25 |
Sumitomo Pharma Oncology, Inc. |
Alvocidib-prodrugs mit erhöhter bioverfügbarkeit
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
WO2017015387A1
(en)
|
2015-07-20 |
2017-01-26 |
Tufts University |
Biodegradable silk ear tubes
|
MX2018001289A
(es)
|
2015-08-03 |
2018-04-30 |
Tolero Pharmaceuticals Inc |
Terapias de combinacion para el tratamiento del cancer.
|
EP3370719A1
(de)
|
2015-11-02 |
2018-09-12 |
Novartis AG |
Dosierungsplan für einen phosphatidylinositol-3-kinase-inhibitor
|
MX2018006781A
(es)
|
2015-12-03 |
2018-11-09 |
Agios Pharmaceuticals Inc |
Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap.
|
WO2017189832A1
(en)
|
2016-04-29 |
2017-11-02 |
Trustees Of Tufts College |
An artificial silk based innervated cornea
|
WO2018006037A1
(en)
|
2016-07-01 |
2018-01-04 |
Trustees Of Tufts College |
Innervated artificial skin
|
US11248313B2
(en)
|
2016-08-01 |
2022-02-15 |
Trustees Of Tufts College |
Biomimetic mechanical tension driven fabrication of nanofibrillar architecture
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
KR20190099260A
(ko)
|
2016-12-19 |
2019-08-26 |
톨레로 파마수티컬스, 인크. |
프로파일링 펩티드 및 감도 프로파일링을 위한 방법
|
CR20190338A
(es)
|
2016-12-22 |
2019-09-09 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso
|
US20200000713A1
(en)
|
2017-01-20 |
2020-01-02 |
Massachusetts Institute Of Technology |
Injectable polymer micro-depots for controlled local drug delivery
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
CN116003405A
(zh)
|
2017-09-08 |
2023-04-25 |
美国安进公司 |
Kras g12c的抑制剂及其使用方法
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
WO2019075367A1
(en)
|
2017-10-13 |
2019-04-18 |
Tolero Pharmaceuticals, Inc. |
PKM2 ACTIVATORS IN COMBINATION WITH OXYGEN REACTIVE SPECIES FOR THE TREATMENT OF CANCER
|
WO2019089567A1
(en)
|
2017-10-30 |
2019-05-09 |
Massachusetts Institute Of Technology |
Layer-by-layer nanoparticles for cytokine therapy in cancer treatment
|
WO2019094702A1
(en)
|
2017-11-10 |
2019-05-16 |
Cocoon Biotech Inc. |
Ocular applications of silk-based products
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
MX2020010836A
(es)
|
2018-05-04 |
2021-01-08 |
Amgen Inc |
Inhibidores de kras g12c y métodos para su uso.
|
CA3099045A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
EP3802535B1
(de)
|
2018-06-01 |
2022-12-14 |
Amgen, Inc |
Kras-g12c-inhibitoren und verfahren zur verwendung davon
|
WO2019241157A1
(en)
|
2018-06-11 |
2019-12-19 |
Amgen Inc. |
Kras g12c inhibitors for treating cancer
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
WO2020023910A1
(en)
|
2018-07-26 |
2020-01-30 |
Tolero Pharmaceuticals, Inc. |
Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
US11053226B2
(en)
|
2018-11-19 |
2021-07-06 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
MX2021006544A
(es)
|
2018-12-04 |
2021-07-07 |
Sumitomo Pharma Oncology Inc |
Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
|
AR117490A1
(es)
|
2018-12-20 |
2021-08-11 |
Amgen Inc |
Inhibidores de kif18a
|
JP2022513967A
(ja)
|
2018-12-20 |
2022-02-09 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤として有用なヘテロアリールアミド
|
MX2021007104A
(es)
|
2018-12-20 |
2021-08-11 |
Amgen Inc |
Inhibidores de kif18a.
|
WO2020132653A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
KR20210146290A
(ko)
|
2019-02-12 |
2021-12-03 |
스미토모 다이니폰 파마 온콜로지, 인크. |
헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
|
KR20210146288A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로사이클릴 화합물 및 이의 용도
|
WO2020180768A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
KR20210141621A
(ko)
|
2019-03-22 |
2021-11-23 |
스미토모 다이니폰 파마 온콜로지, 인크. |
Pkm2 조정제를 포함하는 조성물 및 그를 사용한 치료 방법
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
CA3140392A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
WO2021002984A1
(en)
|
2019-05-30 |
2021-01-07 |
Massachusetts Institute Of Technology |
Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids
|
CA3142608A1
(en)
|
2019-06-04 |
2020-12-10 |
Cocoon Biotech Inc. |
Silk-based products, formulations, and methods of use
|
EP4007756A1
(de)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a-inhibitoren
|
JP2022542967A
(ja)
|
2019-08-02 |
2022-10-07 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
MX2022001296A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
EP4048671A1
(de)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidinderivate als kras-sg12c- und kras-g12d-inhibitoren zur behandlung von krebs
|
CR20220243A
(es)
|
2019-11-04 |
2022-08-04 |
Revolution Medicines Inc |
Inhibidores de ras
|
CA3159561A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
MX2022005357A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
BR112022008858A2
(pt)
|
2019-11-08 |
2022-09-06 |
Revolution Medicines Inc |
Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
|
IL292315A
(en)
|
2019-11-14 |
2022-06-01 |
Amgen Inc |
Improved synthesis of a kras g12c inhibitory compound
|
US20230192682A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
BR112022010086A2
(pt)
|
2020-01-07 |
2022-09-06 |
Revolution Medicines Inc |
Dosagem do inibidor de shp2 e métodos de tratamento de câncer
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
AU2021344830A1
(en)
|
2020-09-03 |
2023-04-06 |
Revolution Medicines, Inc. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
CN116457358A
(zh)
|
2020-09-15 |
2023-07-18 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
CN112661639A
(zh)
*
|
2020-12-07 |
2021-04-16 |
浙江工业大学 |
一种4-乙酰丁酸酯类化合物合成方法
|
EP4267250A1
(de)
|
2020-12-22 |
2023-11-01 |
Qilu Regor Therapeutics Inc. |
Sos1-inhibitoren und verwendungen davon
|
EP4334324A1
(de)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Kovalente ras-inhibitoren und verwendungen davon
|
CN118234731A
(zh)
|
2021-05-05 |
2024-06-21 |
锐新医药公司 |
Ras抑制剂
|
IL308195A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors for cancer treatment
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
US20230399313A1
(en)
*
|
2022-06-10 |
2023-12-14 |
Advenchen Pharmaceuticals, LLC |
Biological activities of 5-(2-(4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)ethyl)-5-azaspiro[2.4]-heptan-7-ol crystalline, phosphoric acid salt and its enantiomers
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|